A
Atossa Therapeutics, Inc. (ATOS)
NCM – Real Time Price. Currency in USD
1.88
+0.11 (6.21%)
At close: Jun 26, 2026, 4:00 PM EDT
1.89
+0.01 (0.53%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.88
+0.11 (6.21%)
At close: Jun 26, 2026, 4:00 PM EDT
1.89
+0.01 (0.53%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
| Name | Position |
|---|---|
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
| Mr. Mark J. Daniel CPA | Chief Financial Officer |
| Ms. Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Ms. Janet Rose Rea MSPH, RAC | Senior Vice President of Research & Development |
| Date | Type | Document |
|---|---|---|
| 2026-06-11 | 8-K | atos-20260610.htm |
| 2026-05-08 | 8-K | atos-20260507.htm |
| 2026-05-08 | 10-Q | atos-20260331.htm |
| 2026-04-16 | 8-K | d107774d8k.htm |
| 2026-03-30 | DEF 14A | atos-20260330.htm |
| 2026-03-30 | ARS | ars_2025_10k_def_14a_202.pdf |
| 2026-03-25 | 8-K | atos-20260324.htm |
| 2026-03-25 | 10-K | atos-20251231.htm |
| 2026-03-20 | PRE 14A | atos-20260320.htm |
| 2026-02-20 | 8-K | d100198d8k.htm |